Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)

This study has been completed.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Eli Lilly and Company
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Jorg Dietrich, M.D., Ph.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00916630
First received: June 5, 2009
Last updated: September 21, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2015
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)